Preventing Sepsis

Lactillion commercializes lactoferrin for the prevention and treatment of sepsis. Lactoferrin can reduce the risk of death from severe sepsis and septic shock by reducing the growth of bacteria in the blood and by improving the immune system’s initial response to these invading pathogens. Sepsis is the second leading killer of people admitted to hospital intensive care units. There are 750,000 severe sepsis patients each year in the U.S., of these, 215,000 (~ 30%) die within 3 months.

Lactillion has exclusive rights to issued patents on the normal human lactoferrin gene, the recombinant lactoferrin protein, and the use of lactoferrin for the treatment of SIRS, the precursor to sepsis.

Watch a short Overview

Sepsis Knowledge Community
Collection of people, organizations,
science and medical information relevant
to sepsis disease, treatment and prevention.

Natural Protection Against Pathogens

The lactoferrin protein is normally found in mother's milk and is part of the passive immunity that protects a baby from pathogens. Lactillion harnesses two of lactoferrin's primary functions to prevent sepsis from developing or to decrease the risk of death from ongoing infections:

• Antimicrobial - it binds and sequesters iron that is needed for bacterial growth. Lactoferrin's antimicrobial peptide regions also bind to and prevent pathogens from multiplying.

• Immunomodulatory - it down regulates harmful cytokines that can lead to shock while at the same time induces differentiation and growth of immune system cells needed to combat infections.